This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.

开始日期2026-06-30

申办/合作机构

Indapta Therapeutics, Inc.

NCT06815003

/ Not yet recruiting临床2期IIT

Phase-2 Study of Vedolizumab Plus Post-Transplant Cyclophosphamide and Short Course Tacrolimus for Graft-versus-Host Disease Prevention After Reduced Intensity Conditioning Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplantation

This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a donor. Giving reduced conditioning chemotherapy before an allogeneic HCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new stem cells to grow using less than standard doses of chemotherapy. Sometimes, the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Vedolizumab is a monoclonal antibody, which is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). It may reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus suppresses the immune system by preventing the activation of certain types of immune cells. Giving vedolizumab plus PTCy and short course tacrolimus may be effective at preventing GVHD after allogeneic HCT.

开始日期2026-01-08

申办/合作机构

City of Hope National Medical Center

[+1]

NCT06474663

/ Not yet recruiting临床1期IIT

A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating with Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

To find the recommended dose of the drug combination cladribine, cytarabine, decitabine, and sorafenib in participants with relapsed/refractory AML, MPAL, and ALAL.

开始日期2025-12-31

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与 RNRs 相关的临床结果

登录后查看更多信息

100 项与 RNRs 相关的转化医学

登录后查看更多信息

0 项与 RNRs 相关的专利（医药）

登录后查看更多信息

5,350

项与 RNRs 相关的文献（医药）

2025-12-31·Emerging Microbes & Infections

Hypermutability of Mycolicibacterium smegmatis due to ribonucleotide reductase-mediated oxidative homeostasis and imbalanced dNTP pools

Article

作者: Wang, Hengyu ; Kang, Jian ; Zhang, Xuelian ; Zhang, Xiao ; Zheng, Yuqing ; Chi, Mingzhe ; Chen, Jiazhen ; Zhang, Yu ; Wang, Yu ; Hu, Youwei ; Di, Yuchang

Ribonucleotide reductase (RNR) catalyzes the synthesis of four deoxyribonucleoside triphosphates (dNTPs), which are essential for DNA replication. Although dNTP imbalances reduce replication fidelity and elevate mutation rates, the impact of RNR dysfunction on Mycobacterium tuberculosis (Mtb) physiology and drug resistance remains unknown. Here, we constructed inducible knockdown strains for the RNR R1 subunit NrdE in Mtb and Mycolicibacterium smegmatis (Msm). NrdE knockdown significantly impaired growth and metabolic imbalances, indirectly disrupting oxidative homeostasis and mycolic acid synthesis, while increasing levels of intracellular ROS accumulation and enhancing cell wall permeability. Additionally, we developed genomic mutant strains, Msm-Y252A and Msm-Q255A, featuring targeted point mutations in the substrate-specific site (S-site) of the RNR loop domain, which determines NDP reduction specificity. The Msm-Y252A displayed a 1.9-fold decrease in dATP and increases in dGTP (1.6-fold), dTTP (9.0-fold), and dCTP (1.3-fold). In contrast, Msm-Q255A exhibited elevated intracellular levels of dGTP (1.6-fold), dTTP (6.1-fold), and dATP (1.5-fold), while dCTP levels remained unchanged. Neither the NrdE knockdown strain nor the S-site mutants exhibited direct resistance development; however, they both showed genomic instability, enhancing the emergence of rifampicin-resistant mutants, even with a 70-fold and a 25-fold increase in mutation frequency for Msm-Y252A and Msm-Q255A, respectively. This study demonstrates that NrdE is integral to Mycobacterium survival and genomic stability and that its RNR dysfunction creates a mutagenic environment under selective pressure, indirectly contributes to the development of drug resistance, positioning NrdE as an effective target for therapeutic strategies and a valuable molecular marker for early detection of drug-resistant Mtb.

2025-12-01·Clinical Proteomics

Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer

Article

作者: Larsen, Matt ; Haaland, Benjamin ; Kohli, Manish ; Lee, Hyejung ; Dechet, Christopher B ; O'Neil, Brock ; Gupta, Sumati ; Fadlullah, Muhammad Zaki ; Swami, Umang ; Ampaw, Enos ; Neibling, Anna ; Tward, Jonathan ; Lin, Tengda ; Johnson, Skyler B ; Hanson, Claire ; Wang, Liang ; Shen, Jincheng ; Maughan, Benjamin L ; Lloyd, Jennifer ; Schmidt, Bogdana ; Tan, Aik-Choon

BACKGROUNDPlasma-based high-plex proteomic profiling were performed in prostate cancer (PC) patients using the Olink® Explore Proximity Extension Assay to identify plasma proteins associated in different PC states and to explore potential prognostic biomarkers. The progressive PC states include local, organ-confined PC (local PC), metastatic hormone-sensitive PC (mHSPC) and metastatic castrate-resistant PC (mCRPC).METHODSPlasma samples were uniformly processed from 84 PC patients (10 patients with local PC; 29 patients with mHSPC; 45 patients with mCRPC). A proteome-wide association study was performed to identify proteins differentially overexpressed in progressive cancer states. Specifically, a sequential screening approach was employed where proteins overexpressed from one disease state were assessed for overexpression in the progressive disease state. Linear regression, analysis of variance, and t-tests were used for this approach. Differentially expressed proteins (DEPs) in mCRPC were then used to construct a prognostic model for overall survival (OS) in mCRPC patients using the Cox Proportional Hazard Model. The predictive performance of this model was assessed using time-dependent area under the receiver operating characteristic curves (tAUC) in an independent sample of mCRPC patients. The tAUC of the prognostic model was then compared to that of a model excluding DEPs to evaluate the added value of circulatory proteins in predicting survival.RESULTSOf 736 tumor-associated proteins, 26 were differentially expressed across local PC, mHSPC, and mCRPC states. Among these, 20 were overexpressed in metastatic states compared to local, and in mCRPC compared to mHSPC states. Of these 20 proteins, Ribonucleoside-diphosphate reductase subunit M2 (RRM2) was identified as a prognostic biomarker for OS in mCRPC, with a hazard ratio of 2.30 (95% confidence interval (CI) 1.17-4.51) per normalized expression unit increase. The tAUC of the model including previously identified clinical prognostic factors was 0.62 (95% CI 0.29-0.91), whereas the model that includes RRM2 with clinical prognostic factors was 0.87 (95% CI 0.51-0.98).CONCLUSIONSPlasma proteome profiling can identify novel circulatory DEPs associated with mCRPC state survivals. Overexpression of RRM2 is linked to poor mCRPC survival and its inclusion alongside conventional prognostic factors enhances the predictive performance of the prognostic model.

2025-05-01·Cellular Signalling

Study on the effects and mechanism of RRM2 on three gynecological malignancies

Article

作者: Yang, Luhan ; Yu, Junxu ; Hao, Rushan ; Wang, Junfeng ; Zhang, Hongping ; Zheng, Bingrong ; Ge, Jing

Cervical cancer, endometrial cancer, and ovarian cancer are the three most common gynecological malignancies. Their occurrence seriously affects women's health and life. Despite aggressive treatments, some patients still find it difficult to benefit from available therapies. Ribonucleic acid reductase subunit M2 (RRM2) is a limiting RNR enzyme involved in DNA synthesis and damage repair and plays a crucial role in many key cellular processes such as cell proliferation, migration, invasion, and senescence. Many studies have also shown that RRM2 also has a significant impact on tumor progression. However, the role of RRM2 in gynecological tumors has not been systematically studied. Our bioinformatics analysis of datasets related to cervical, endometrial, and ovarian cancers revealed that RRM2 is a significantly differentially expressed gene common to these cancers. We found that RRM2 was significantly overexpressed in cervical, endometrial, and ovarian cancer tissues and cells, exhibiting overall pro-oncogenic effects. RRM2 promoted cell proliferation, migration invasion, angiogenesis, and cell cycle in gynecological tumors while inhibiting apoptosis. The potential oncogenic effects of RRM2 in gynecologic tumor cell lines were further demonstrated using the RRM2 inhibitor Triapine (3-AP). These pro-tumorigenic effects may then be mediated through the involvement of RRM2 in the p53 and Akt/mTOR signaling pathways, altering the expression of p53 and Akt/mTOR. Thus, RRM2 is potentially a candidate gene for the unified diagnosis of cervical, endometrial, and ovarian cancers.

项与 RNRs 相关的新闻（医药）

2025-04-15

·SYNAPSE

Norgine strengthens rare disease portfolio with acquisition of Theravia

Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines. Transaction further establishes Norgine's position as a partner of choice for commercialising rare and specialty pharmaceuticals in Europe. PARIS, April 15, 2025 /PRNewswire/ -- Norgine and Theravia announced today that they have entered into a definitive agreement under which Norgine will acquire Theravia, an international pharmaceutical company specialising in cutting-edge treatments for patients with rare and debilitating conditions. Recent deals with Fennec Pharma for PEDMARQSI® and X4 Pharma for mavorixafor demonstrate Norgine's strong emphasis on driving growth in rare disease and specialty medicines through acquisitions and in-licensing. Theravia's innovations have resulted in successful launches of life-saving medications which have changed patient outcomes worldwide. Theravia has several products in the rare disease space, including SIKLOS®, for adults and children with sickle cell disease, and ORPHACOL®, a medicine for adults and children who have a genetic disorder that affects bile production by the liver. These products span both the rare haematology and rare hepatology therapeutic areas and are complementary to Norgine's existing rare and specialty portfolio. The development of Theravia in the past few years has been supported by its majority shareholder Mérieux Equity Partners, a healthcare dedicated investment firm based in France. said Janneke van der Kamp, Chief Executive Officer, Norgine. Franck Hamalian, Chief Executive Officer, Theravia, added: With the acquisition of Theravia, Norgine will now have six core products in its rare disease portfolio (PEDMARQSI®, eflornithine, mavorixafor, AGILUS®, SIKLOS® and ORPHACOL®) thereby comprising a franchise of critical scale with the ability to be a key growth driver in the medium-to-long-term. Norgine looks forward to building on this transaction as we continue to strengthen our platform for future acquisitions and in-licensing opportunities to drive growth. The transaction remains subject to obtaining customary regulatory approvals from the competent authorities.

上市批准并购孤儿药临床3期

2025-02-26

·ioncology

ELCC 2025丨欧洲肺癌大会中国好声音：报告和研究汇总

点上方蓝字“ioncology”关注我们，然后点右上角“…”菜单，选择“设为星标” ELCC 2025 微专辑扫描二维码可查看更多内容 2025年欧洲肺癌大会（ELCC）将于3月26日～28日在法国巴黎召开。目前，ELCC官网已公布会议日程（LBA标题尚未公布），来自中国大陆的专家有超过100项研究入选。本文汇总2025 ELCC日程中中国大陆专家的报告以及研究，供读者参考。演讲&讨论专场：Controversy session：Invasive mediastinal re-staging after Chemo-0 neoadjuvant therapy: Pros and cons 争议讨论：化疗/免疫新辅助治疗后的侵入性纵隔重新分期的利与弊讨论专家：吴楠丨北京大学肿瘤医院时间：3月26日15.15-16.15 地点：Room N03 壁报摘要号：12P 英文标题：Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small-cell lung cancer (sqNSCLC): 5y update from the phase 3 CameL-sq trial 中文标题：卡瑞利珠单抗联合化疗作为晚期鳞状非小细胞肺癌（NSCLC）一线疗法：III期CameL-sq试验5年更新讲者：周彩存丨上海市东方医院摘要号：14P 英文标题：Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: a single-arm, phase 2 trial 中文标题：针对一线化疗免疫治疗后的NSCLC寡残留病灶进行巩固立体定向放疗：单臂II期试验讲者：Hongru Chen 丨上海摘要号：19P 英文标题：Subgroup Analysis of First-Line Camrelizumab Plus Chemotherapy in Brain Metastases of NSCLC: Results from the CTONG 2003 Trial 中文标题：一线卡瑞利珠单抗联合化疗治疗NSCLC脑转移的亚组分析：CTONG 2003试验结果讲者：黎扬斯丨广东省人民医院摘要号：25P 英文标题：Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase 3 POSEIDON extended China cohort 中文标题：度伐利尤单抗±tremelimumab+化疗作为转移性NSCLC的一线治疗：III期POSEIDON扩展中国队列的结果讲者：王洁丨中国医学科学院肿瘤医院摘要号：30P 英文标题：Clinical Characteristics and Survival Outcomes of Long-Term Responders for advanced Non-Small Cell Lung Cancer Patients with First-line PD-1/PD-L1 Inhibitors: A Multicenter Retrospective Study 中文标题：接受一线PD-1/PD-L1抑制剂治疗的晚期NSCLC患者长期应答者的临床特征和生存结局：一项多中心回顾性研究讲者：Zhijuan Du丨北京摘要号：31P 英文标题：Camrelizumab Plus Chemotherapy as First-Line Treatment for Advanced Non-squamous NSCLC with Brain Metastases: Final overall survival results from the CAP-BRAIN trial 中文标题：卡瑞利珠单抗+化疗作为晚期非鳞NSCLC脑转移的一线治疗：CAP-BRAIN试验的最终总生存结果讲者：侯雪丨中山大学肿瘤防治中心摘要号：34P 英文标题：Polymeric micelles paclitaxel (pm-Pac), carboplatin combined with sintilimab in the first-line treatment of advanced non-squamous non-small cell lung cancer(nsq-NSCLC): Phase II study 中文标题：聚合胶束紫杉醇、卡铂联合信迪利单抗一线治疗晚期非鳞NSCLC的II期研究讲者：周云丨江苏省肿瘤医院摘要号：35P 英文标题：Clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: a systematic review and meta-analysis 中文标题：晚期NSCLC患者一线治疗后接受癌症疫苗的临床和安全性结局：一项系统性综述和荟萃分析讲者：Shaoyi Chen丨北京摘要号：37P 英文标题：Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-NSCLC): programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase 3 RATIONALE-304 trial 中文标题：替雷利珠单抗联合化疗作为局部晚期或转移性非鳞状NSCLC一线治疗：III期随机RATIONALE-304试验PD-L1表达≥50%亚组分析讲者：于雁丨哈尔滨医科大学附属肿瘤医院摘要号：39P 英文标题：Real World Efficacy and Safety of Anlotinib in NSCLC Previously Treated with Immune Checkpoint Inhibitors 中文标题：安罗替尼在既往接受过免疫检查点抑制剂治疗的NSCLC患者中的实际疗效和安全性讲者：董宇超丨上海长海医院摘要号：46P 英文标题：Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study 中文标题：比较卡瑞利珠单抗、帕博利珠单抗、替雷利珠单抗和信迪利单抗作为NSCLC患者一线治疗：一项回顾性研究讲者：于韶荣丨江苏省肿瘤医院摘要号：47P 英文标题：Efficacy and safety of cadonilimab-based therapies in non-small cell lung cancer patients with progression after immunotherapy 中文标题：基于卡度尼利单抗的疗法对免疫治疗后进展的NSCLC患者的疗效和安全性讲者：于韶荣丨江苏省肿瘤医院摘要号：50P 英文标题：The impact of prior bevacizumab on the efficacy of anlotinib in advanced non-squamous non-small cell lung cancer 中文标题：既往使用贝伐珠单抗对安罗替尼治疗晚期非鳞NSCLC疗效的影响讲者：王佳蕾丨复旦大学附属肿瘤医院摘要号：54P 英文标题：Efficacy and Safety of Firmonertinib 160mg Combined with Intrathecal Injection Pemetrexed in NSCLC Patients with EGFR Mutations and Leptomeningeal Metastases 中文标题：伏美替尼（160 mg）联合鞘内注射培美曲塞治疗脑膜转移的EGFR突变NSCLC患者的疗效和安全性讲者：李晓燕丨北京天坛医院摘要号：55P 英文标题：Clinical value and optimal timing of cranial stereotactic radiotherapy for third-generation EGFR-TKI-treated NSCLC with baseline limited brain metastases 中文标题：基线伴有局限性脑转移NSCLC患者经第三代EGFR-TKI治疗后，颅内立体定向放射治疗的临床价值和应用最佳时机讲者：Silai Yu丨上海摘要号：57P 英文标题：Safety and Efficacy of Aumolertinib Treatment in Patients with advanced NSCLC Harboring 20ins and uncommon EGFR Mutations (AIM) 中文标题：阿美替尼治疗携带EGFR 20ins和其他罕见EGFR突变的晚期NSCLC患者的安全性和有效性：AIM研究讲者：方文峰丨中山大学附属肿瘤医院摘要号：61P 英文标题：Response to first-line osimertinib plus pemetrexed/carboplatin in EGFR-mutant advanced NSLCLC with high PD-L1 expression 中文标题：PD-L1高表达EGFR突变晚期NSCLC患者对一线奥希替尼+培美曲塞/卡铂的治疗反应讲者：Chengdi Weng丨广州摘要号：62P 英文标题：Firmonertinib (formerly furmonertinib) combined with anlotinib in patients with treatment-naive EGFR-mutant non-small-cell lung cancer: updated results from FOCUS-A study 中文标题：伏美替尼+安罗替尼治疗初治EGFR突变NSCLC患者：FOCUS-A研究的最新结果讲者：韩宝惠丨上海市胸科医院摘要号：64P 英文标题：A real-world study of furmonertinib in uncommon EGFR mutated non-small cell lung cancer with central nervous system metastasis 中文标题：伏美替尼治疗罕见EGFR突变、中枢神经系统转移NSCLC患者的真实世界研究讲者：方申存丨南京市胸科医院摘要号：66P 英文标题：Long-term Follow-up of Limertinib (ASK120067) in Patients with Locally Advanced or Metastatic EGFR T790M NSCLC: A multicentre, single-arm, phase 2b study 中文标题：利厄替尼（ASK120067）在局部晚期或转移性EGFR T790MNSCLC患者中的长期随访：一项多中心、单臂、IIb期研究讲者：邬麟丨湖南省肿瘤医院摘要号：67P 英文标题：A Phase II Study of Sunvozertinib Combined with Anlotinib in EGFR-TKIs resistant EGFRm Advanced NSCLC Patients（WU-KONG9）中文标题：舒沃替尼+安罗替尼治疗EGFR-TKIs耐药EGFR突变晚期NSCLC患者的II期WU-KONG9研究讲者：胡洁丨复旦大学附属中山医院摘要号：68P 英文标题：Survival Impact of Immunotherapy(IO) after Chemo-failure in EGFR-mutated NSCLC：A post-hoc analysis of the Orient-31 trial 中文标题：化疗治疗失败后免疫治疗对EGFR突变NSCLC患者生存的影响：Orient-31研究的事后分析讲者：李子明丨上海市胸科医院摘要号：69P 英文标题：PET/Fluorescence Dual-Modal Tracing for Targeted Inhibition of RRM2 to Overcome Osimertinib Resistance in Lung Cancer 中文标题：为克服肺癌对奥希替尼的耐药性，采用PET/荧光双模式追踪RRM2靶向抑制讲者：Jinyu Zhu丨北京摘要号：72P 英文标题：Optimizing Treatment Strategies for EGFR 21L858R mutation Non-Small Cell Lung Cancer with Brain Metastases: A Real-world Analysis of First-Line EGFR-TKI Efficacy 中文标题：优化EGFR 21L858R突变NSCLC脑转移患者的治疗策略：一线EGFR-TKI治疗疗效的真实世界分析讲者：陈丽昆丨中山大学肿瘤防治中心摘要号：73P 英文标题：Real-World Post-progression Analysis of First-Line Osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH Study) 中文标题：一线奥希替尼治疗中国EGFR突变晚期NSCLC的真实世界进展后分析：FLOURISH研究讲者：周建娅丨浙江大学医学院附属第一医院摘要号：75P 英文标题：Firmonertinib plus anlotinib for first-line treatment of advanced EGFR L858R mutated non-small cell lung cancer 中文标题：伏美替尼+安罗替尼一线治疗EGFR L858R突变晚期NSCLC 讲者：周进丨四川省肿瘤医院摘要号：77P 英文标题：EGFR-mutant Advanced NSCLC Patients Continuously Benefit From Aumolertinib as Post Secone-Line Treatment 中文标题：EGFR突变晚期NSCLC患者持续受益于阿美替尼作为二线后治疗讲者：刘智华丨江西省肿瘤医院摘要号：80P 英文标题：Final Overall Survival and Long-term Safety Outcomes of Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 (METex14) Mutation: An Update from a Phase 3b Study 中文标题：赛沃替尼治疗MET 14外显子跳跃突变（METex14）局部晚期或转移性NSCLC患者的最终总生存期和长期安全性结果：IIIb期研究的更新讲者：虞永峰丨上海市胸科医院摘要号：90P 英文标题：Efficacy of subsequent therapy following the progression of crizotinib in advanced ROS1+ NSCLC in real word setting 中文标题：在真实世界中，克唑替尼治疗晚期ROS1阳性NSCLC进展后的后续治疗疗效讲者：Zihua Zou丨北京摘要号：91P 英文标题：Intracranial efficacy of crizotinib in advanced ROS1+NSCLC in real world setting 中文标题：真实世界中克唑替尼治疗晚期ROS1阳性NSCLC的颅内疗效讲者：Zihua Zou丨北京摘要号：111P 英文标题：A web-based calculator to Predict the Occurrence of Severe Immune-Related Adverse Events in Non-Small Cell Lung Cancer: Based on a Prospective Study 中文标题：网络计算器用于预测NSCLC患者发生严重免疫相关不良事件的前瞻性研究讲者：宋鹏丨中国人民解放军总医院摘要号：121P 英文标题：Clinical Application and Potential Benefits of En-bloc Biopsy Based on Minimally Invasive Surgery for Advanced Lung Cancer 中文标题：基于微创手术的En-bloc活检在晚期肺癌中的临床应用和潜在获益讲者：Jianfu Li丨广州摘要号：126TiP 英文标题：An Open-Label, Single-Arm, Phase Ib Exploratory Study to Evaluate the Safety and Efficacy of Golidocitinib in Combination with Anti-PD-1 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1 Containing Regimens 中文标题：一项开放标签、单组Ib期探索性研究，旨在评估戈利昔替尼+抗PD-1药物在含抗PD-1药物方案经治局部晚期或转移性NSCLC患者中的疗效和安全性讲者：钟华丨上海市胸科医院摘要号：130TiP 英文标题：High-Dose Aumolertinib as First-Line Treatment in Advanced NSCLC Patients harboring EGFR 21L858R Mutation (AHEAD) 中文标题：高剂量阿美替尼作为EGFR 21L858R突变晚期NSCLC患者的一线治疗：AHEAD研究讲者：林立平丨广州医科大学附属番禺中心医院摘要号：141P 英文标题：Deep learning-based prediction of lung cancer visceral pleural invasion during thoracoscopic surgery: A multicenter study 中文标题：基于深度学习为胸部手术预测肺癌内脏胸膜侵犯情况：一项多中心研究讲者：Hao Xu丨北京摘要号：142P 英文标题：Identification of the Lymph Node Metastasis Atlas and Optimal Lymph Node Dissection Strategy in Patients with Resectable Lung Invasive Mucinous Adenocarcinoma: A Real-World Multicentre Study 中文标题：确认可切除肺浸润性粘液腺癌的淋巴结转移图谱和最佳淋巴结清扫策略：一项多中心真实世界研究讲者：赫捷丨中国医学科学院肿瘤医院摘要号：143P 英文标题：Microwave Ablation Versus Lobectomy for Ground-Glass Opacity Nodules in the Hilar Region: A Multicenter Prospective Real-World Study on Efficacy and Safety 中文标题：微波消融vs肺叶切除术治疗肺门部毛玻璃影结节的疗效和安全性：一项多中心前瞻性真实世界研究讲者：Wangrui Liu丨上海摘要号：144P 英文标题：Perioperative Immunotherapy Treatment in Resectable Non-Small Cell Lung Cancer with KRAS Mutation: A Real-World Study (Peri-R-01) 中文标题：携带KRAS突变的可切除NSCLC的围手术期免疫治疗：Peri-R-01真实世界研究讲者：钟华教授丨上海市胸科医院摘要号：145P 英文标题：Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A NSCLC with High risk factors and EGFR-sensitizing Mutations (APPOINT) 中文标题：阿美替尼作为可切除I A期NSCLC（伴有高风险因素和EGFR敏感突变）患者辅助治疗的疗效和安全性：APPOINT研究讲者：韩宝惠丨上海市胸科医院摘要号：149P 英文标题：Comparative investigation of neoadjuvant chemoimmunotherapy versus perioperative (chemo)immunotherapy in resectable non–small cell lung cancer: A real-world retrospective study 中文标题：新辅助化疗/免疫治疗vs围术期（化疗）免疫治疗用于可切除NSCLC：一项回顾性真实世界研究讲者：Sini N. Li丨杭州摘要号：151P 英文标题：Real-world Adjuvant Treatment Patterns in Chinese Patients with Resected Stages I to III EGFR-mutated NSCLC: A Multi-center Observational Study (ADDRESS, CATO-2001) 中文标题：已切除I-III期EGFR突变NSCLC中国患者的真实辅助治疗模式：多中心ADDRESS观察研究（CATO-2001）讲者：梁文华丨广州医科大学附属第一医院摘要号：155P 英文标题：Survival after wedge resection, segmentectomy and lobectomy for clinical stage IA non-small cell lung cancer: a network meta-analysis and systematic review 中文标题：临床IA期NSCLC患者接受楔形切除、肺段切除和肺叶切除后的生存率：一项网络荟萃分析和系统综述讲者：沈建飞丨浙江省台州医院摘要号：162P 英文标题：A Real world study of Adjuvant furmonertinib in patients with stage IA-IIIA EGFR-mutant non-small-cell lung cancer 中文标题：伏美替尼辅助治疗IA-IIIA EGFR突变NSCLC患者的真实世界研究讲者：Ye Jiayue丨杭州摘要号：164P 英文标题：The Clinical Response and Safety of Neoadjuvant Alectinib in Lung Adenocarcinoma with ALK Rearrangement: A Two-Center Retrospective Study 中文标题：新辅助阿来替尼治疗ALK重排肺腺癌的临床疗效和安全性：一项双中心回顾性研究讲者：Liang Shi丨北京摘要号：165P 英文标题：Adjuvant Aumolertinib for Resected EGFR-Mutated Stage IA2-ⅢA Non-Small-Cell Lung Cancer: Updated Results From A multiple-center real-world experience 中文标题：EGFR突变IA2-ⅢA期NSCLC术后接受阿美替尼辅助治疗：一项多中心真实世界经验的结果更新讲者：Qingyi Zhang丨杭州摘要号：166P 英文标题：MRD Evaluation of Aumolertinib in EGFR Mutation-positive stage IB and stage IA2-3 NSCLC After Complete Surgical Resection: A Multicenter, Single-arm, Open-lable Study 中文标题：EGFR突变阳性IB期和IA2-III期NSCLC完全切除后基于MRD选择阿美替尼治疗：一项多中心、单组、开放标签的研究讲者：程超丨中山大学附属第一医院摘要号：176TiP 英文标题：Perioperative Adebrelimab Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Multicenter, Phase II Trial 中文标题：围手术期阿得贝利单抗+化疗治疗携带EGFR突变的可切除NSCLC：一项多中心II期试验讲者：Gebang Wang丨沈阳摘要号：177TiP 英文标题：Phase II Clinical Study of Adebrelimab Combined with Carboplatin, Albumin-Bound Paclitaxel, and Recaticimab in Perioperative Treatment of Resectable NSCLC 中文标题：阿得贝利单抗+卡铂/白蛋白结合型紫杉醇+瑞卡西单抗作为可切除NSCLC围手术期治疗的II期临床研究讲者：Jinghui Wang丨北京摘要号：179TiP 英文标题：Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer (NEOLORA) 中文标题：洛拉替尼作为IB-IIIB期ALK重排NSCLC的新辅助治疗讲者：杨帆丨北京大学人民医院摘要号：197P 英文标题：Efficacy and Safety of Induction Chemo-Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Multicenter Retrospective Study 中文标题：诱导化疗/免疫治疗在不可切除III期NSCLC中的有效性和安全性：一项多中心回顾性真实世界研究讲者：Wenlu Chen丨太原摘要号：205P 英文标题：EGFR-TKI Combined with Chemotherapy versus EGFR-TKI Alone for locally advanced EGFR-mutant NSCLC: A Real-World Study 中文标题：EGFR-TKI联合化疗vs 单用EGFR-TKI治疗局部晚期EGFR突变NSCLC：一项真实世界研究讲者：Yu Jiang丨广州摘要号：209P 英文标题：Four-Year Outcomes with Perioperative Toripalimab plus Chemotherapy in Resectable Stage III Non-Small Cell Lung Cancer (NeoTAP01 Study) 中文标题：围手术期特瑞普利单抗+化疗治疗可切除III期NSCLC的NeoTAP01研究4年结果讲者：Yuheng Zhou丨广州摘要号：212P 英文标题：Recurrence in Patients with Non–Small Cell Lung Cancer Achieving Pathological Complete Response after Neoadjuvant Treatment 中文标题：新辅助治疗后达到病理完全缓解（pCR）的NSCLC患者的复发情况讲者：Yuechun Lin丨广州摘要号：214P 英文标题：Refining Central Lung Cancer Surgery: Uniportal Video-Assisted Thoracic Surgery with Three-Dimensional Vascular Mapping After Neoadjuvant Chemoimmunotherapy 中文标题：改良中央型肺癌手术：在新辅助化疗/免疫治疗后采用单孔胸腔镜手术结合三维血管成像讲者：罗志林丨重庆医科大学附属第三医院摘要号：215P 英文标题：Safety and Necessity of Mediastinal Lymph Nodes Dissection Omission Following Nodal Clearance with Neoadjuvant Immunochemotherapy in cN0/N1 Non-Small Cell Lung Cancer 中文标题：在新辅助免疫/化疗清除cN0/N1非小细胞肺癌淋巴结后，省略纵隔淋巴结的安全性和必要性讲者：Yuheng Zhou丨广州摘要号：216P 英文标题：Prognostic Impacts of Skip Metastasis in N2a and N2b Subgroups in Non-Small Cell Lung Cancer：Insights from a Large Cohort 中文标题：NSCLC患者N2a和N2b亚组跳跃转移对预后的影响：一项大型队列结果带来的启示讲者：Shenhua Liang丨广州摘要号：228P 英文标题：Type VII Collagen Enhances Matrix Viscoelasticity and Modulates Immune Response in Advanced Lung Adenocarcinoma 中文标题：VII型胶原增强晚期肺腺癌患者的基质的粘弹性并调节免疫反应讲者：Pengxu Kong丨杭州摘要号：237P 英文标题：125I particles implantation is an effective therapy for oligo-progression during immunotherpy. 中文标题：125I粒子植入是免疫治疗期间寡进展的有效治疗方法讲者：Yu Yao丨西安摘要号：254P 英文标题：Serial monitoring of cerebrospinal fluid in lung cancer patients with brain metastases via the ommaya reservoir as a predictive indicator of therapeutic efficacy and clinical prognosis 中文标题：对肺癌脑转移患者脑脊液进行Ommaya囊连续监测，作为治疗效果和临床预后的预测指标讲者：方申存丨南京市胸科医院摘要号：258P 英文标题：Pan-cancer analyses reveal tissue-type-specific intracellular bacteria in lung metastatic cancer 中文标题：泛癌分析揭示了肺转移癌中的组织类型特异性细胞内细菌讲者：Haiming Chen丨福州摘要号：259P 英文标题：Association of Gut Microbiome with Radiotherapy Efficacy in Lung Cancer Patients with Brain Metastases 中文标题：肺癌脑转移患者的肠道微生物组与放射治疗疗效的关系讲者：夏铀铀丨连云港市第一人民医院摘要号：264P 英文标题：Innovative Portable Breathomic Device For Early Non-Invasive Differentiation Of Benign And Malignant Lung Nodules 中文标题：创新便携式呼吸装置，用于早期无创性鉴别肺结节的良恶性讲者：梁恒瑞丨广州医科大学附属第一医院摘要号：265P 英文标题：Association Between Digestive System Diseases and Lung Cancer Risk: A Comprehensive Evaluation based on UK Biobank 中文标题：消化系统疾病与肺癌风险之间的关联：基于英国Biobank的综合评估结果讲者：Yi Feng丨广州摘要号：266P 英文标题：Association Between Serum Branched-Chain Amino Acids and Cancer Risk: Findings from a Prospective Cohort Study in the UK Biobank 中文标题：血清支链氨基酸与癌症风险的关系：基于英国Biobank的前瞻性队列研究结果讲者：Yi Feng丨广州摘要号：276P 英文标题：A multicenter exhaled breath metabolomics lung cancer screening model based on PTR-TOF MS 中文标题：基于质子转移反应飞行时间质仪（PTR-TOF-MS）开发多中心、呼气代谢组学肺癌筛查模型讲者：Chen Huang丨成都摘要号：278P 英文标题：Dynamic Machine Learning for Early Lung Cancer Identification Using Longitudinal Clinical and Laboratory Data 中文标题：纵向临床和实验室数据用于早期肺癌识别的动态机器学习讲者：叶文君丨广州医科大学附属第一医院摘要号：279P 英文标题：Study on screening and diagnosis model of smokers based on PTR-TOF-MS 中文标题：研究PTR-TOF-MS用于吸烟者的筛查和诊断模型讲者：Chen Huang丨成都摘要号：300P 英文标题：CT-based intratumoral and peritumoral radiometric characteristics accurately predict the risk of distant metastasis in small cell lung cancer 中文标题：基于CT评估瘤内和瘤周放射学特征，可准确预测小细胞肺癌远处转移的风险讲者：王苒丨安徽医科大学第一附属医院摘要号：302P 英文标题：Phase 2 study of the efficacy and safety of BNT327/PM8002 plus systemic chemotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) 中文标题：评估BNT327/PM8002联合全身化疗一线治疗ES-SCLC的有效性和安全性的II期研究讲者：程颖丨吉林省肿瘤医院摘要号：304P 英文标题：Prognostic markers and Molecular Insights: Navigating SCLC with Liver Metastasis 中文标题：伴肝转移的小细胞肺癌的预后标志物和分析分析讲者：Jing Ding丨成都摘要号：308P 英文标题：Real-world outcomes in extensive-stage small cell lung cancer treated with first-line serplulimab: The nationwide observational ASTRUM-005R study 中文标题：一线斯鲁利单抗治疗ES-SCLC的真实世界结果：全国观察性ASTRUM-005R研究讲者：邬麟丨湖南省肿瘤医院摘要号：310P 英文标题：Final overall survival (OS) of surufatinib plus PD-1/PD-L1 antibodies as maintenance therapy following first line (1L) platinum-based chemotherapy (Chemo) plus PD-1/PD-L1 antibodies in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) 中文标题：ES-SCLC患者在一线铂基化疗+PD-1/PD-L1抗体治疗后，使用索凡替尼+PD-1/PD-L1抗体作为维持治疗的最终总生存讲者：胡毅丨中国人民解放军总医院摘要号：317P 英文标题：Impact of Induction Chemotherapy Cycles on the Efficacy of First-Line Atezolizumab Combined with Chemotherapy in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) 中文标题：诱导化疗周期对一线阿替利珠单抗联合化疗治疗ES-SCLC疗效的影响讲者：Mengxing You丨北京摘要号：318P 英文标题：Impact of Prophylactic Cranial Irradiation on Survival in Extensive-Stage Small Cell Lung Cancer Receiving First-Line Chemoimmunotherapy: A Propensity Score-Matched Study 中文标题：预防性颅脑照射对ES-SCLC患者接受一线化疗/免疫治疗的生存的影响：一项倾向评分匹配研究讲者：范云丨浙江省肿瘤医院摘要号：320P 英文标题：Lysine-specific Demethylase 1A (LSD1) inhibition attenuates phenotypic transition and delays the tumor relapse to radioimmunotherapy in small cell lung cancer 中文标题：赖氨酸特异性去甲基化酶1A（LSD1）抑制可减弱SCLC表型转化并延缓放射免疫所致的肿瘤复发讲者：Hui Wang丨成都摘要号：322P 英文标题：Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer 中文标题：小细胞外囊泡miRNAs作为预测ES-SCLC免疫/化疗治疗疗效的生物标志物讲者：Wei Zhang丨上海摘要号：328P 英文标题：The Prognostic Analysis and Model Establishment of Central and Peripheral Small Cell Lung Cancer 中文标题：中央型SCLC和周围型SCLC的预后分析及模型建立讲者：Yu Yao丨西安摘要号：329P 英文标题：Intracranial efficacy of YL201, a novel B7-H3-targeting antibody-drug conjugate (ADC), in patients (pts) with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) 中文标题：新型b7-h3抗体偶联药物（ADC）YL201在小细胞肺癌和非小细胞肺癌患者中的颅内疗效讲者：赵洪云丨中山大学肿瘤防治中心摘要号：331P 英文标题：A single-arm, open-label, prospective, single-center clinical study on the treatment of patinum-resistant relapse small cell lung cancer with nab-paclitaxel combined with apatinib 中文标题：单臂、开放标签、前瞻性、单中心临床研究：nab-紫杉醇联合阿帕替尼治疗铂耐药复发小细胞肺癌讲者：杨雪丨北京大学肿瘤医院摘要号：332P 英文标题：Updated phase II efficacy and safety results of BNT327/PM8002 combined with paclitaxel as second-line (2L) therapy in small cell lung cancer (SCLC) 中文标题：BNT327/PM8002联合紫杉醇二线治疗小细胞肺癌的疗效和安全性：II期研究的结果更新讲者：程颖丨吉林省肿瘤医院摘要号：333P 英文标题：Safety and effectiveness of adebrelimab as second- or later-line treatment in extensive-stage small-cell lung cancer: a prospective, real-world study 中文标题：阿得贝利单抗作为ES-SCLC二线或后线治疗的安全性和有效性：一项前瞻性真实世界研究讲者：Xiaoli Liu丨青岛摘要号：336P 英文标题：Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis 中文标题：度伐利尤单抗作为局限期小细胞肺癌（LS-SCLC）的巩固治疗：ADRIATIC中国亚组分析讲者：程颖丨吉林省肿瘤医院摘要号：337P 英文标题：Safety and Effectiveness of hyper-fractionated Simultaneous Integrated Boost in Definitive Chemoradiation for Limited-Stage Small Cell Lung Cancer 中文标题：超分割同步整合放疗用于LS-SCLC根治性放化疗的安全性和有效性讲者：Wenqiang Guan丨自贡摘要号：338P 英文标题：Preoperative immunochemotherapy versus chemotherapy for patients with stage I–IIIB small-cell lung cancer 中文标题：术前免疫化疗 vs 术前化疗治疗I-IIIB期小细胞肺癌患者讲者：Jiacong Liu丨杭州摘要号：339P 英文标题：A Retrospective Real-World Study of Neoadjuvant Chemotherapy in Patients with Resectable Small-Cell Lung Cancer 中文标题：可切除小细胞肺癌患者接受新辅助化疗的回顾性真实世界研究讲者：Wengang Zhang丨上海摘要号：343TiP 英文标题：Maintenance Therapy with Fuzuloparib plus Adebrelimab for ES-SCLC after First-Line Induction with Fuzuloparib plus Adebrelimab and Chemotherapy: A Prospective, Single-Arm, Phase II Clinical Study 中文标题：ES-SCLC患者接受氟唑帕利+阿得贝利单抗+化疗一线诱导治疗后，采用氟唑帕利+阿得贝利单抗维持治疗：一项前瞻性单组II期临床研究讲者：Huiru Xu丨太原摘要号：344TiP 英文标题：Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with adebrelimab plus chemotherapy (CLOG2402-ADAPT): a multi-center, single-arm, phase 2 clinical trial 中文标题：ES-SCLC患者接受一线阿得贝利单抗联合化疗诱导后，采用阿得贝利单抗+阿帕替尼维持治疗：一项多中心、单组、II期CLOG2402-ADAPT临床试验讲者：Lingyun Zhang丨沈阳摘要号：348P 英文标题：Pulsed High-Dose Fractionated Radiotherapy Combined with Enhanced Immunotherapy in the Treatment of Driver Gene-Negative Advanced Non-small-cell Lung Cancer: A Clinical Study 中文标题：脉冲高剂量分割放疗+强化免疫治疗用于驱动基因阴性晚期非小细胞肺癌：一项临床研究讲者：苗传望丨山东第一医科大学附属肿瘤医院摘要号：351P 英文标题：The Application of Peripheral Blood Immune Profiling in Personalized Treatment of Advanced Lung Cancer: A Nomogram Approach 中文标题：外周血免疫谱在晚期肺癌个性化治疗中的应用：一种列线图模型讲者：苗传望丨山东第一医科大学附属肿瘤医院摘要号：356P 英文标题：DDR2 inhibition reveals a T cell immune checkpoint that controls lung cancer immunosurveillance 中文标题：DDR2抑制揭示了控制肺癌免疫监视的T细胞免疫检查点讲者：Shuai Zhang丨武汉摘要号：359P 英文标题：Prognostic role of B7H3 in non-small cell lung cancer patients treated with immune checkpoint inhibitors 中文标题：B7H3预测NSCLC患者接受免疫检查点抑制剂治疗预后的作用讲者：智欣欣丨上海市肺科医院摘要号：372P 英文标题：Sympathetic Signals Promote Immunosuppressive Neutrophils for Tumor Progression in the Lung 中文标题：交感信号促进免疫抑制性中性粒细胞在肺肿瘤进展中发挥作用讲者：Ruoyi Jin丨北京摘要号：375P 英文标题：Multi-Omics Revealed Unique Metabolic Resistance Mechanisms to Third-Generation EGFR-TKI in EGFR-Mutant Non-Small Cell Lung Cancer 中文标题：多组学揭示EGFR突变NSCLC患者对第三代EGFR-TKI的独特代谢耐药机制讲者：Ruyun Gao丨北京摘要号：381P 英文标题：Empowering Global Oncology: DBS-TARGET Enables High-Sensitivity Mutation Detection Anywhere 中文标题：赋能全球肿瘤学：利用DBS-TARGET在任何地区实现高灵敏度的基因突变检测讲者：Liu Jingjing丨合肥摘要号：382P 英文标题：Unveiling DEFB1 as a Novel Driver and Promising Therapeutic Target in Lung Adenocarcinoma 中文标题：DEFB1作为新的肺腺癌驱动因素和有前景的治疗靶点讲者：Cheng Zhan丨上海摘要号：387P 英文标题：Machine learning-assisted metabolomics for development model of predicting 1-year overall survival in lung cancer patients with malignant pleural effusion 中文标题：机器学习辅助代谢组学用于模型开发：预测肺癌伴恶性胸腔积液患者的1年总生存讲者：Wang Sufei丨武汉摘要号：392P 英文标题：Integrating Wearable Devices and Electronic Patient Reported Outcomes for Continuous Perioperative Monitoring: Novel Evidence for Enhanced Recovery after Thoracic Surgery 中文标题：整合围手术期的可穿戴设备监测结果和电子患者报告结局（ePROs）：胸外科加速康复外科的新证据讲者：Runchen Wang丨广州摘要号：399P 英文标题：Microplastic Exposure in COPD Alters the Immune Microenvironment: Implications for Tumor-Promoting Inflammation 中文标题：阻塞性肺疾病（COPD）患者的微塑料暴露改变了免疫微环境：对肿瘤促炎症作用的影响讲者：Wangrui Liu丨上海摘要号：404P 英文标题：The 41BB agonist potentiates the therapeutic efficacy of irreversible electroporation combined with immune adjuvants for lung cancer by promoting not only tissue-resident memory CD8 + T cell but also cDC1 responses 中文标题：41BB激动剂通过促进组织驻留记忆CD8+ T细胞和cDC1应答来增强不可逆电穿孔+免疫辅助疗法治疗肺癌的疗效讲者：Yu Feng丨苏州摘要号：413P 英文标题：Classifying Multiple Lung Cancers by Spatial Microenvironment: Tertiary Lymphoid Structures at Interface Zone as Immune Hubs and Prognostic Determinants 中文标题：通过空间微环境对多发性肺癌进行分类：界面区的三级淋巴结构作为免疫枢纽和预后决定因素讲者：Xiaoqiu Yuan丨北京摘要号：414P 英文标题：Exosome Whisperers: Decoding SPHK1's Role in Cisplatin-induced immune escape of NSCLC 中文标题：外泌体“解密者”：解码SPHK1在顺铂诱导的NSCLC免疫逃逸中的作用讲者：Huan Ga丨西安摘要号：426P 英文标题：Ototoxicity and Safety Profile of Capmatinib in NSCLC: Insights from Real-World FAERS Data (2020-2023) Session Name中文标题：卡马替尼治疗NSCLC的耳毒性和安全性：基于真实世界FAERS数据库（2020-2023）的分析讲者：徐思琪丨福建医科大学协和临床医学院（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床2期临床结果

2025-01-16

·医药笔记

NMIBC完全缓解率84%：强生TAR-200递交上市申请

▎Armstrong 2025年1月15日，强生宣布启动递交TAR-200的上市申请，用于治疗卡介苗（BCG）不应答的高危非肌肉侵袭性膀胱癌（HR-NMIBC）伴原位癌（CIS）患者。此次递交通过实时肿瘤审评（RTOR）项目，允许FDA在完全申请正式递交之前就开始审评以加快进度。 TAR-200为一种膀胱内局部给药的新型递送系统，采用一种双重小片设计，材质为硅聚合物半透小管，吉西他滨在膀胱持续缓慢释放。根据去年ESMO会议上公布的SunRISe-1临床数据，队列二中TAR-200单药治疗的完全缓解率高达83.8%。Cetrelimab单药治疗组完全缓解率则为46.4%。总结近年来NMIBC新药层出不穷，IL-15去年刚刚获批，更多新药还在不断取得临床突破。除了TAR-200，CG Oncology的溶瘤病毒疗法CG0070也取得非常亮眼的疗效数据和安全性数据，且已经获得FDA授予的突破疗法认证。国内方面，乐普生物拥有CG0070的大中华区权益，前几天刚刚被拟纳入突破治疗药物程序。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

快速通道突破性疗法抗体药物偶联物申请上市